To identify lncRNAs specifically expressed in darolutamide-resistant prostate cancer cells, we performed RNA sequencing on darolutamide-resistant cells (DaroR), parental LNCaP cells treated with DMSO (Vehicle), LNCaP cells treated with 10 nM synthetic AR agonist R1881 (R1881), and LNCaP cells transiently treated with 10 μM darolutamide (Daro) for 24 h. The gene discussed is AR; the disease is prostate carcinoma.